Efficacy and safety of Tripterygium agents in treatment of psoriasis: a systematic review and network meta-analysis.

PhytomedicineJun 22, 2026 (epub)
Clinical ResearchDermatology

Nai-Xuan Lin, Jing-Jie He, Peng-Bo Gao et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the efficacy and safety of Tripterygium agents for psoriasis treatment, analyzing 43 trials. Combination therapy with Tripterygium glycoside and acitretin significantly reduced the Psoriasis Area and Severity Index (PASI) score by a mean difference of -3.96, while monotherapy showed no significant effect.

Key findings

  • Combination therapy with Tripterygium glycoside and acitretin reduced PASI score by -3.96.
  • The total effective rate for combination therapy was significantly higher with an odds ratio of 3.02.
  • Tripterygium glycoside + acitretin ranked first in improving PASI score at 98.41%.

Why it matters

Understanding the efficacy and safety of Tripterygium agents can help clinicians make informed decisions regarding treatment options for psoriasis, particularly in cases where traditional therapies may be insufficient.

What to keep in mind

All included studies were published in Chinese or English, leading to potential selection bias.

Source

PubMed · PMID 42378804

Published in Phytomedicine. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.